-+ 0.00%
-+ 0.00%
-+ 0.00%

Citizens Maintains Market Outperform on Crinetics Pharmaceuticals, Lowers Price Target to $108

Benzinga·11/07/2025 13:43:22
Listen to the news
Citizens analyst Jonathan Wolleben maintains Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Market Outperform and lowers the price target from $143 to $108.